“Toward a system plan for transforming cancer care to a molecular-based approach”: Recommendations from an expert panel
- DOI: 10.1016/j.atg.2014.06.002
- Get rights and content
- Under a Creative Commons license
Leading cancer experts convened for a one day Think Tank to develop practical recommendations for transforming cancer care from an organ-based approach to a molecular-based approach. The event took place on May 30, 2013 in Chicago prior to ASCO and was keynoted by Dr. Richard Wilson, Director, The Genome Institute at Washington University School of Medicine.
Members
- •
- Rick Wilson, Director, The Genome Institute at Washington Univ. School of Medicine
- •
- Judy Garber, Director, Cancer Risk/Prevention Clinic, Dana Farber
- •
- Shashikant Kulkarni, Head of Clinical Genomics, Wash. University School of Medicine
- •
- Shyamali Singhal, Medical Director of the Cancer Center, El Camino Hospital
- •
- Nickolas Papadopoulos, Director of Translational Genetics, Johns Hopkins Medicine
- •
- John Sweetenham, CMO, Huntsman Cancer Institute
- •
- Paula Rieger, CEO, Oncology Nurses Society
- •
- Nazneen Aziz, Director of Molecular Medicine, College of American Pathologists
- •
- Mary Zutter, Director, Tumor-Host Interaction Program, Vanderbilt Ingram Cancer Center
- •
- Tim McDaniel, Director of Scientific Research, Illumina Inc.
- •
- Les Paul, CMO, Caris Life Science
- •
- Dawn Van Dam, CEO, Health Connexions
- •
- Anthony Flynn, Associate, AcceleratorH
Think Tank Background
At the 2011 Personalized Medicine Conference1 at Harvard Medical School, 80% of attendees voted “genomic interpretation” as the top challenge in adopting genomics in routine medical care. Given the industry-wide collaboration involved in interpretation, an I-Study2 set out to determine how well the healthcare ecosystem is aligned with the goals of genomic medicine and to offer recommendations to accelerate this important advance.
The 2012 I-study conducted interviews with more than 55 industry leaders across twelve healthcare sectors: pharmaceuticals, contract research organizations, academic laboratories, commercial laboratories, diagnostic companies, decision support suppliers, healthcare providers, sequencing providers, healthcare equipment makers, care management, healthcare IT, and payers. An expert panel representing science, medical, technology, and business disciplines reviewed the transcripts and produced a comprehensive set of findings and recommendations.
One of the recommendations, originally suggested by Dr. Rick Wilson of Washington University, was: “Prepare a System Plan for Molecular-based Treatment of Cancer”. Many interviewees felt that cancer is best treated as a molecular disorder and not an organ disorder and reported frustration with the present mismatch between a molecular approach and the organ-based structure of the present healthcare system. Hence, a study recommendation called for a systematic plan to transform cancer care based on the current molecular understanding of the disease, specifically that cancer is more similar across organs than previously understood.
.png)
No hay comentarios:
Publicar un comentario